The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Lou Whiteman, Contributing Aerospace Analyst at The Motley Fool, discusses SpaceX's volatile first week of trading and what investors should watch next.
Seth Goldstein, Senior Equity Analyst and Chair of the Electric Vehicle Committee at Morningstar, breaks down the robotaxi race and EV adoption trends.
Andrew Rush, CEO of Star Catcher Industries, joins us to discuss how wireless power transmission could reshape satellite technology and space communications.
